Interventions of Interest:
- sotatercept (Merck & Co)
For questions please contact Yamaya Jean, Program Manager, at yjean@icer.org.
View the Key Stakeholder List.
Pulmonary Arterial Hypertension
An assessment of sotatercept
Public Meeting
December 2023
Assessment Status
Open
Upcoming Milestone
Revised Scoping DocumentView
Main Review
December 1, 2023
Midwest CEPAC
The Midwest CEPAC’s 2023 public meeting on pulmonary arterial hypertension.
Public Comment Period
See Full Timeline
05/15/2023 - 06/05/2023
Public Comments on Draft Scoping Document
Related Assessments & Policy Papers.
05/15/2023 - 06/05/2023
Public Comments on Draft Scoping Document
06/13/2023
Revised Scoping Document
06/20/2023
Research Protocol
Please find the research protocol here:
08/09/2023
Model Analysis Plan
09/25/2023 - 10/23/2023
Public Comments on Draft Evidence Report
11/14/2023
Evidence Report
12/01/2023
Evidence Presentation
01/08/2024
Public Comments
OpenView
Closed